<VariationArchive VariationID="4302" VariationName="NM_000157.4(GBA1):c.84dup (p.Leu29fs)" VariationType="Duplication" Accession="VCV000004302" Version="39" RecordType="classified" NumberOfSubmissions="13" NumberOfSubmitters="13" DateLastUpdated="2024-07-29" DateCreated="2015-08-31" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="19341" VariationID="4302">
      <GeneList>
        <Gene Symbol="GBA1" FullName="glucosylceramidase beta 1" GeneID="2629" HGNC_ID="HGNC:4177" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>1q22</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="155234452" stop="155244627" display_start="155234452" display_stop="155244627" Strand="-" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NW_003315906.1" start="39475" stop="49650" display_start="39475" display_stop="49650" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="155204238" stop="155214652" display_start="155204238" display_stop="155214652" Strand="-" />
          </Location>
          <OMIM>606463</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000157.4(GBA1):c.84dup (p.Leu29fs)</Name>
      <CanonicalSPDI>NC_000001.11:155240660:C:CC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>1q22</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="155240660" stop="155240661" display_start="155240660" display_stop="155240661" variantLength="1" positionVCF="155240660" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="155210451" stop="155210452" display_start="155210451" display_stop="155210452" variantLength="1" positionVCF="155210451" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
      </Location>
      <OtherNameList>
        <Name>84GG</Name>
      </OtherNameList>
      <ProteinChange>L29fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001005741.2" sequenceAccession="NM_001005741" sequenceVersion="2" change="c.84dup">
            <Expression>NM_001005741.2:c.84dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="protein">
          <ProteinExpression sequenceAccessionVersion="NP_001005741.1" sequenceAccession="NP_001005741" sequenceVersion="1" change="p.Leu29Alafs*18">
            <Expression>NP_001005741.1:p.Leu29Alafs*18</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.155210452dup" Assembly="GRCh37">
            <Expression>NC_000001.10:g.155210452dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.11" sequenceAccession="NC_000001" sequenceVersion="11" change="g.155240661dup" Assembly="GRCh38">
            <Expression>NC_000001.11:g.155240661dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009783.1" sequenceAccession="NG_009783" sequenceVersion="1" change="g.9037dup">
            <Expression>NG_009783.1:g.9037dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000157.4" sequenceAccession="NM_000157" sequenceVersion="4" change="c.84dup" MANESelect="true">
            <Expression>NM_000157.4:c.84dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000148.2" sequenceAccession="NP_000148" sequenceVersion="2" change="p.Leu29fs">
            <Expression>NP_000148.2:p.Leu29fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001005741.3" sequenceAccession="NM_001005741" sequenceVersion="3" change="c.84dup">
            <Expression>NM_001005741.3:c.84dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001005741.1" sequenceAccession="NP_001005741" sequenceVersion="1" change="p.Leu29fs">
            <Expression>NP_001005741.1:p.Leu29fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001005742.3" sequenceAccession="NM_001005742" sequenceVersion="3" change="c.84dup">
            <Expression>NM_001005742.3:c.84dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001005742.1" sequenceAccession="NP_001005742" sequenceVersion="1" change="p.Leu29fs">
            <Expression>NP_001005742.1:p.Leu29fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001171812.2" sequenceAccession="NM_001171812" sequenceVersion="2" change="c.84dup">
            <Expression>NM_001171812.2:c.84dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001165283.1" sequenceAccession="NP_001165283" sequenceVersion="1" change="p.Leu29fs">
            <Expression>NP_001165283.1:p.Leu29fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001171811.2" sequenceAccession="NM_001171811" sequenceVersion="2" change="c.-146-584dup">
            <Expression>NM_001171811.2:c.-146-584dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000157.3" sequenceAccession="NM_000157" sequenceVersion="3" change="c.84dupG">
            <Expression>NM_000157.3:c.84dupG</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001005742.2" sequenceAccession="NM_001005742" sequenceVersion="2" change="c.84dupG">
            <Expression>NM_001005742.2:c.84dupG</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA221415" DB="ClinGen" />
        <XRef ID="GTR000321628" DB="Genetic Testing Registry (GTR)" />
        <XRef ID="GTR000500692" DB="Genetic Testing Registry (GTR)" />
        <XRef ID="GTR000603993" DB="Genetic Testing Registry (GTR)" />
        <XRef Type="Allelic variant" ID="606463.0014" DB="OMIM" />
        <XRef Type="rs" ID="387906315" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00005" Source="Exome Aggregation Consortium (ExAC)" />
        <AlleleFrequency Value="0.00005" Source="The Genome Aggregation Database (gnomAD), exomes" />
        <AlleleFrequency Value="0.00005" Source="Trans-Omics for Precision Medicine (TOPMed)" />
        <AlleleFrequency Value="0.00006" Source="The Genome Aggregation Database (gnomAD)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000157.4(GBA1):c.84dup (p.Leu29fs) AND Gaucher disease type I" Accession="RCV000004543" Version="19">
        <ClassifiedConditionList TraitSetID="1190">
          <ClassifiedCondition DB="MedGen" ID="C1961835">Gaucher disease type I</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-12-26" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000157.4(GBA1):c.84dup (p.Leu29fs) AND Gaucher disease" Accession="RCV000587723" Version="15">
        <ClassifiedConditionList TraitSetID="6268">
          <ClassifiedCondition DB="MedGen" ID="C0017205">Gaucher disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2020-01-13" SubmissionCount="4">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000157.4(GBA1):c.84dup (p.Leu29fs) AND not provided" Accession="RCV000790704" Version="24">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-01-16" SubmissionCount="5">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000157.4(GBA1):c.84dup (p.Leu29fs) AND multiple conditions" Accession="RCV001004138" Version="9">
        <ClassifiedConditionList TraitSetID="11607">
          <ClassifiedCondition DB="MedGen" ID="C1961835">Gaucher disease type I</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0268250">Gaucher disease type II</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0268251">Gaucher disease type III</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1856476">Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000157.4(GBA1):c.84dup (p.Leu29fs) AND multiple conditions" Accession="RCV002476926" Version="8">
        <ClassifiedConditionList TraitSetID="12838">
          <ClassifiedCondition DB="MedGen" ID="C1842704">Gaucher disease perinatal lethal</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1961835">Gaucher disease type I</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0268250">Gaucher disease type II</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0268251">Gaucher disease type III</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1856476">Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0752347">Lewy body dementia</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C3160718">Parkinson disease, late-onset</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-07-20" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-01-16" NumberOfSubmissions="13" NumberOfSubmitters="13" DateCreated="2015-08-31" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10079102</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">10777718</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">10796875</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">11783951</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">1348297</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17875915</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19513999</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">1961718</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21228398</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21700325</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21742527</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22975760</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25653295</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25933391</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25946768</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26096741</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27717005</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29471591</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29842932</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">7789963</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8432537</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8487270</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8516282</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8889578</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9153297</ID>
        </Citation>
        <Citation Type="general">
          <URL>http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=GBA</URL>
        </Citation>
        <Citation Type="general">
          <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/63c92f1a-076d-4067-bf85-f7278faa8820</URL>
        </Citation>
        <Citation Type="review" Abbrev="GeneReviews">
          <ID Source="PubMed">20301446</ID>
          <ID Source="BookShelf">NBK1269</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1190" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1362" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Gaucher disease type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, noncerebral juvenile</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glucocerebrosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acid beta-glucosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher's disease, type 1</ElementValue>
                <XRef ID="Gaucher+Disease+Type+1/3002" DB="Genetic Alliance" />
                <XRef ID="62201009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GBA DEFICIENCY</ElementValue>
                <XRef Type="MIM" ID="230800" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD I</ElementValue>
                <XRef Type="MIM" ID="230800" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease type I</ElementValue>
                <XRef ID="MONDO:0009265" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">GD1</ElementValue>
                <XRef Type="MIM" ID="230800" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2441" />
                <XRef ID="2441" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="PubMed">18197057</ID>
                <ID Source="pmc">3110977</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19888064</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="355" DB="Orphanet" />
              <XRef ID="77259" DB="Orphanet" />
              <XRef ID="C1961835" DB="MedGen" />
              <XRef ID="MONDO:0009265" DB="MONDO" />
              <XRef Type="MIM" ID="230800" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="11607" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1364" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Subacute neuronopathic Gaucher's disease</ElementValue>
                <XRef ID="Gaucher+Disease+Type+3/3004" DB="Genetic Alliance" />
                <XRef ID="5963005" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD 3</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, juvenile and adult, cerebral</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, chronic neuronopathic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, subacute neuronopathic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD III</ElementValue>
                <XRef Type="MIM" ID="231000" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher Disease, Type 3</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease type III</ElementValue>
                <XRef ID="MONDO:0009267" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2443" />
                <XRef ID="2443" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="355" DB="Orphanet" />
              <XRef ID="77261" DB="Orphanet" />
              <XRef ID="C0268251" DB="MedGen" />
              <XRef ID="MONDO:0009267" DB="MONDO" />
              <XRef Type="MIM" ID="231000" DB="OMIM" />
            </Trait>
            <Trait ID="1362" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Gaucher disease type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, noncerebral juvenile</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glucocerebrosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acid beta-glucosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher's disease, type 1</ElementValue>
                <XRef ID="Gaucher+Disease+Type+1/3002" DB="Genetic Alliance" />
                <XRef ID="62201009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GBA DEFICIENCY</ElementValue>
                <XRef Type="MIM" ID="230800" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD I</ElementValue>
                <XRef Type="MIM" ID="230800" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease type I</ElementValue>
                <XRef ID="MONDO:0009265" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">GD1</ElementValue>
                <XRef Type="MIM" ID="230800" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2441" />
                <XRef ID="2441" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="PubMed">18197057</ID>
                <ID Source="pmc">3110977</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19888064</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="355" DB="Orphanet" />
              <XRef ID="77259" DB="Orphanet" />
              <XRef ID="C1961835" DB="MedGen" />
              <XRef ID="MONDO:0009265" DB="MONDO" />
              <XRef Type="MIM" ID="230800" DB="OMIM" />
            </Trait>
            <Trait ID="1363" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Acute neuronopathic Gaucher's disease</ElementValue>
                <XRef ID="Gaucher+Disease+Type+2/3003" DB="Genetic Alliance" />
                <XRef ID="12246008" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, infantile cerebral</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, acute neuronopathic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD II</ElementValue>
                <XRef Type="MIM" ID="230900" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease type II</ElementValue>
                <XRef ID="MONDO:0009266" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">GD2</ElementValue>
                <XRef Type="MIM" ID="230900" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2442" />
                <XRef ID="2442" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="77260" DB="Orphanet" />
              <XRef ID="C0268250" DB="MedGen" />
              <XRef ID="MONDO:0009266" DB="MONDO" />
              <XRef Type="MIM" ID="230900" DB="OMIM" />
            </Trait>
            <Trait ID="2161" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome</ElementValue>
                <XRef ID="MONDO:0009268" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GAUCHER DISEASE, TYPE IIIC</ElementValue>
                <XRef Type="MIM" ID="231005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606463.0006" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease type 3C</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12504" />
                <XRef ID="12504" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <XRef ID="2072" DB="Orphanet" />
              <XRef ID="C1856476" DB="MedGen" />
              <XRef ID="MONDO:0009268" DB="MONDO" />
              <XRef Type="MIM" ID="231005" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="6268" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="14198" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Gaucher disease</ElementValue>
                <XRef ID="Gaucher+Disease/3000" DB="Genetic Alliance" />
                <XRef ID="MONDO:0018150" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acute cerebral Gaucher disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cerebroside lipidosis syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher splenomegaly</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sphingolipidosis 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glucocerebrosidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glucosylceramidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glucosyl cerebroside lipidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Kerasin lipoidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Kerasin thesaurismosis</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8233" />
                <XRef ID="8233" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="PubMed">18197057</ID>
                <ID Source="pmc">3110977</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19888064</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2011">
                <URL>http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Carrier-Screening-ACT-SheetAshkenazi-Jewish-Genetic-Disorders.aspx</URL>
                <CitationText>American College of Medical Genetics ACT Sheet, Carrier Screening ACT Sheet Ashkenazi Jewish Genetic Disorders</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="355" DB="Orphanet" />
              <XRef ID="C0017205" DB="MedGen" />
              <XRef ID="MONDO:0018150" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="12838" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1913" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Gaucher disease perinatal lethal</ElementValue>
                <XRef ID="MONDO:0011945" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease collodion type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, perinatal-lethal form</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10675" />
                <XRef ID="10675" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <XRef ID="85212" DB="Orphanet" />
              <XRef ID="C1842704" DB="MedGen" />
              <XRef ID="MONDO:0011945" DB="MONDO" />
              <XRef Type="MIM" ID="608013" DB="OMIM" />
            </Trait>
            <Trait ID="1364" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Subacute neuronopathic Gaucher's disease</ElementValue>
                <XRef ID="Gaucher+Disease+Type+3/3004" DB="Genetic Alliance" />
                <XRef ID="5963005" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD 3</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, juvenile and adult, cerebral</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, chronic neuronopathic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, subacute neuronopathic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD III</ElementValue>
                <XRef Type="MIM" ID="231000" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher Disease, Type 3</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease type III</ElementValue>
                <XRef ID="MONDO:0009267" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2443" />
                <XRef ID="2443" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="355" DB="Orphanet" />
              <XRef ID="77261" DB="Orphanet" />
              <XRef ID="C0268251" DB="MedGen" />
              <XRef ID="MONDO:0009267" DB="MONDO" />
              <XRef Type="MIM" ID="231000" DB="OMIM" />
            </Trait>
            <Trait ID="1362" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Gaucher disease type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, noncerebral juvenile</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glucocerebrosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acid beta-glucosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher's disease, type 1</ElementValue>
                <XRef ID="Gaucher+Disease+Type+1/3002" DB="Genetic Alliance" />
                <XRef ID="62201009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GBA DEFICIENCY</ElementValue>
                <XRef Type="MIM" ID="230800" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD I</ElementValue>
                <XRef Type="MIM" ID="230800" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease type I</ElementValue>
                <XRef ID="MONDO:0009265" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">GD1</ElementValue>
                <XRef Type="MIM" ID="230800" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2441" />
                <XRef ID="2441" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="PubMed">18197057</ID>
                <ID Source="pmc">3110977</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19888064</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="355" DB="Orphanet" />
              <XRef ID="77259" DB="Orphanet" />
              <XRef ID="C1961835" DB="MedGen" />
              <XRef ID="MONDO:0009265" DB="MONDO" />
              <XRef Type="MIM" ID="230800" DB="OMIM" />
            </Trait>
            <Trait ID="1363" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Acute neuronopathic Gaucher's disease</ElementValue>
                <XRef ID="Gaucher+Disease+Type+2/3003" DB="Genetic Alliance" />
                <XRef ID="12246008" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, infantile cerebral</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease, acute neuronopathic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GD II</ElementValue>
                <XRef Type="MIM" ID="230900" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Gaucher disease type II</ElementValue>
                <XRef ID="MONDO:0009266" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">GD2</ElementValue>
                <XRef Type="MIM" ID="230900" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2442" />
                <XRef ID="2442" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased ß-glucocerebrosidase, Gaucher disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Gaucher Disease; Decreased beta-glucocerebrosidase activity, 2022</CitationText>
              </Citation>
              <XRef ID="77260" DB="Orphanet" />
              <XRef ID="C0268250" DB="MedGen" />
              <XRef ID="MONDO:0009266" DB="MONDO" />
              <XRef Type="MIM" ID="230900" DB="OMIM" />
            </Trait>
            <Trait ID="3762" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Parkinson's disease</ElementValue>
                <XRef ID="Parkinson+Disease/5603" DB="Genetic Alliance" />
                <XRef ID="49049000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Parkinson disease, late-onset</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">PARKINSON DISEASE, LATE-ONSET, SUSCEPTIBILITY TO</ElementValue>
                <XRef Type="Allelic variant" ID="603680.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="601517.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="157140.0021" DB="OMIM" />
                <XRef Type="Allelic variant" ID="607047.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606463.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606463.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606463.0048" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600075.0001" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Susceptibility to Parkinson's Disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary late onset Parkinson disease</ElementValue>
                <XRef ID="MONDO:0018466" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PARK</ElementValue>
                <XRef Type="MIM" ID="168600" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">PD</ElementValue>
                <XRef Type="MIM" ID="168600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17684" />
                <XRef ID="17684" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301402</ID>
                <ID Source="BookShelf">NBK1223</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <Citation Type="general" Abbrev="EFNS, 2011">
                <ID Source="PubMed">20482602</ID>
              </Citation>
              <XRef ID="411602" DB="Orphanet" />
              <XRef ID="C3160718" DB="MedGen" />
              <XRef ID="MONDO:0008199" DB="MONDO" />
              <XRef Type="MIM" ID="168600" DB="OMIM" />
            </Trait>
            <Trait ID="1243" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Diffuse Lewy body disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Autosomal dominant diffuse Lewy body disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Lewy body dementia</ElementValue>
                <XRef ID="Lewy+body+dementia/4215" DB="Genetic Alliance" />
                <XRef ID="MONDO:0007488" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Lewy Body Disease</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">DLB</ElementValue>
                <XRef Type="MIM" ID="127750" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3243" />
                <XRef ID="3243" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg148</URL>
                <CitationText>UK NICE Clinical guideline (CG148), Urinary incontinence in neurological disease: assessment and management, 2023</CitationText>
              </Citation>
              <XRef ID="C0752347" DB="MedGen" />
              <XRef ID="MONDO:0007488" DB="MONDO" />
              <XRef Type="MIM" ID="127750" DB="OMIM" />
            </Trait>
            <Trait ID="2161" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome</ElementValue>
                <XRef ID="MONDO:0009268" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GAUCHER DISEASE, TYPE IIIC</ElementValue>
                <XRef Type="MIM" ID="231005" DB="OMIM" />
                <XRef Type="Allelic variant" ID="606463.0006" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gaucher disease type 3C</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12504" />
                <XRef ID="12504" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Gaucher disease (GD) encompasses a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type. The identification of three major clinical types (1, 2, and 3) and two other subtypes (perinatal-lethal and cardiovascular) is useful in determining prognosis and management. GD type 1 is characterized by the presence of clinical or radiographic evidence of bone disease (osteopenia, focal lytic or sclerotic lesions, and osteonecrosis), hepatosplenomegaly, anemia and thrombocytopenia, lung disease, and the absence of primary central nervous system disease. GD types 2 and 3 are characterized by the presence of primary neurologic disease; in the past, they were distinguished by age of onset and rate of disease progression, but these distinctions are not absolute. Disease with onset before age two years, limited psychomotor development, and a rapidly progressive course with death by age two to four years is classified as GD type 2. Individuals with GD type 3 may have onset before age two years, but often have a more slowly progressive course, with survival into the third or fourth decade. The perinatal-lethal form is associated with ichthyosiform or collodion skin abnormalities or with nonimmune hydrops fetalis. The cardiovascular form is characterized by calcification of the aortic and mitral valves, mild splenomegaly, corneal opacities, and supranuclear ophthalmoplegia. Cardiopulmonary complications have been described with all the clinical subtypes, although varying in frequency and severity.</Attribute>
                <XRef ID="NBK1269" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301446</ID>
                <ID Source="BookShelf">NBK1269</ID>
              </Citation>
              <XRef ID="2072" DB="Orphanet" />
              <XRef ID="C1856476" DB="MedGen" />
              <XRef ID="MONDO:0009268" DB="MONDO" />
              <XRef Type="MIM" ID="231005" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="24717" SubmissionDate="2017-06-21" DateLastUpdated="2017-06-24" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="606463.0014_GAUCHER DISEASE, TYPE I" title="GBA, 1-BP INS, 84G_GAUCHER DISEASE, TYPE I" />
        <ClinVarAccession Accession="SCV000024717" DateUpdated="2017-06-24" DateCreated="2013-04-04" Type="SCV" Version="4" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1996-01-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In Ashkenazi Jewish patients with type I Gaucher disease (230800), Beutler et al. (1991) identified a 1-bp insertion (84insG) of a second guanine at cDNA nucleotide 84; the mutation was referred to as the '84GG' mutation.</Attribute>
              <Citation>
                <ID Source="PubMed">8889578</ID>
              </Citation>
              <XRef DB="OMIM" ID="230800" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Beutler et al. (1993) found that 10 of 2,305 normal Ashkenazi Jewish individuals were heterozygous for the 84GG insertion mutation, yielding an allele frequency of 0.00217.</Attribute>
              <Citation>
                <ID Source="PubMed">8516282</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Ida et al. (1995) did not identify the 84GG mutation in 32 unrelated Japanese Gaucher patients, of whom 20 were type I, 6 were type II (230900), and 6 were type III (231000).</Attribute>
              <Citation>
                <ID Source="PubMed">7789963</ID>
              </Citation>
              <XRef DB="OMIM" ID="230900" Type="MIM" />
              <XRef DB="OMIM" ID="231000" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA" />
          </GeneList>
          <Name>GBA, 1-BP INS, 84G</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP INS, 84G</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="606463.0014" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">GAUCHER DISEASE, TYPE I</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2291925" SubmissionDate="2019-09-27" DateLastUpdated="2020-02-29" DateCreated="2020-02-29">
        <ClinVarSubmissionID localKey="NC_000001.10:g.155210452dupC|OMIM:230800;230900;231000;231005" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001162869" DateUpdated="2020-02-29" DateCreated="2020-02-29" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.155210452dupC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230800" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230900" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="231000" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="231005" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>BG_GA_2018_SNVs_INDELS</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2354649" SubmissionDate="2020-06-18" DateLastUpdated="2020-07-06" DateCreated="2020-04-06">
        <ClinVarSubmissionID localKey="429|OMIM:230800" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001194194" DateUpdated="2020-07-06" DateCreated="2020-04-06" Type="SCV" Version="2" SubmitterName="Myriad Genetics, Inc." OrgID="507240" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <ReplacedList>
          <Replaced Accession="SCV000485110" DateChanged="2020-07-02" Version="1">
            <Comment Type="MergeComment">SCV000485110 was merged into SCV001194194 to remove duplication.</Comment>
          </Replaced>
        </ReplacedList>
        <Classification DateLastEvaluated="2019-12-26">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">21742527</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8487270</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">1961718</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">1348297</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8432537</ID>
          </Citation>
          <Comment>NM_001005741.2(GBA):c.84dupG(L29Afs*18, aka p.L29Afs*18) is classified as pathogenic in the context of Gaucher disease and may be associated with Type 1, 2 or 3. Sources cited for classification include the following: PMID 21742527, 8487270, 1961718, 1348297 and 8432537. Classification of NM_001005741.2(GBA):c.84dupG(L29Afs*18, aka p.L29Afs*18) is based on the following criteria: The variant causes a premature termination codon that is expected to be targeted by nonsense-mediated mRNA decay and is reported in individuals with the relevant phenotype. Please note: this variant was assessed in the context of healthy population screening.â€šÃ„Ã¶âˆšÃ‘âˆšÂ£</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Myriad Women's Health Autosomal Recessive and X-Linked Classification Criteria (2019)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/vlxza0ea/myriad_women_s_health_autosomal_recessive_and_x-linked_classification_criteria_2019_.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="1" alternateAllele="GC" referenceAllele="G" start="155210451" stop="155210451" variantLength="1" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230800" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6849778</SubmissionName>
          <SubmissionName>SUB7605676</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4892518" SubmissionDate="2022-04-22" DateLastUpdated="2022-04-23" DateCreated="2022-04-23">
        <ClinVarSubmissionID localKey=":Chr.1_155210451_G_GC|Not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002501657" DateUpdated="2022-04-23" DateCreated="2022-04-23" Type="SCV" Version="1" SubmitterName="AiLife Diagnostics, AiLife Diagnostics" OrgID="507594" OrganizationCategory="laboratory" OrgAbbreviation="AiLife" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-12-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">1961718</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21228398</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29471591</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21742527</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17875915</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25653295</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26096741</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22975760</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27717005</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25946768</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21700325</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29842932</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <TypePlatform>NGS</TypePlatform>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="2" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SecondaryFinding">no</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="1" alternateAllele="GC" referenceAllele="G" start="155210451" stop="155210451" variantLength="1" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11350707</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5054060" SubmissionDate="2022-10-25" DateLastUpdated="2022-10-29" DateCreated="2022-10-29">
        <ClinVarSubmissionID localKey="NM_000157.3:c.84dupG|MedGen:C0017205" submittedAssembly="not applicable" />
        <ClinVarAccession Accession="SCV002586409" DateUpdated="2022-10-29" DateCreated="2022-10-29" Type="SCV" Version="1" SubmitterName="GeneReviews" OrgID="500062" OrganizationCategory="resource" OrgAbbreviation="GeneReviews" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no classification provided</ReviewStatus>
          <GermlineClassification>not provided</GermlineClassification>
          <Citation>
            <ID Source="Bookshelf">NBK1269</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000157.3:c.84dupG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0017205" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12205972</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3255206" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2021-05-29">
        <ClinVarSubmissionID localKey="NM_001005741.2:c.84dup|OMIM:127750;168600;230800;230900;231000;231005;608013" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001652791" DateUpdated="2022-12-31" DateCreated="2021-05-29" Type="SCV" Version="2" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-07-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001005741.2:c.84dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="127750" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="168600" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230800" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230900" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="231000" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="231005" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="608013" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
          <SubmissionName>SUB9694437</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3963891" SubmissionDate="2024-01-26" DateLastUpdated="2024-02-04" DateCreated="2021-11-29">
        <ClinVarSubmissionID localKey="bf5b5971e1ffe1295f5c29a1fa61969165177ecd391ab31d311f5b5adad1f60c|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002024193" DateUpdated="2024-02-04" DateCreated="2021-11-29" Type="SCV" Version="3" SubmitterName="Revvity Omics, Revvity" OrgID="167595" OrganizationCategory="laboratory" OrgAbbreviation="PKIG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-08-07">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001005741.3:c.84dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10694847</SubmissionName>
          <SubmissionName>SUB12926214</SubmissionName>
          <SubmissionName>SUB14173319</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1830772" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="4327368|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000936916" DateUpdated="2024-02-14" DateCreated="2019-08-14" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-16">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9153297</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10079102</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10796875</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11783951</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">1961718</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21742527</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25653295</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25933391</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26096741</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27717005</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Leu29Alafs*18) in the GBA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GBA are known to be pathogenic (PMID: 9153297, 10079102, 10796875, 11783951). This variant is present in population databases (rs387906315, gnomAD 0.09%). This premature translational stop signal has been observed in individuals with Gaucher disease and/or Parkinson's disease and dementia with Lewy bodies (PMID: 1961718, 21742527, 25653295, 25933391, 26096741, 27717005). This variant is also known as 84GG. ClinVar contains an entry for this variant (Variation ID: 4302). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.10:g.155210451_155210452insC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB5371970</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1363948" SubmissionDate="2018-01-25" DateLastUpdated="2018-03-17" DateCreated="2018-03-17">
        <ClinVarSubmissionID localKey="NM_001005741.2:c.84dupG|MedGen:C0017205" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000697596" DateUpdated="2018-03-17" DateCreated="2018-03-17" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-06-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">1961718</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10796875</ID>
          </Citation>
          <Comment>Variant summary: The GBA c.84dupG (p.Leu29Alafs) variant results in a premature termination codon, predicted to cause a truncated or absent GBA protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory and other labs/reputable databases in ClinVar (e.g. c.487delG, c.1029delT, c.1265_1319del55, etc.). This variant was found in 6/121380 control chromosomes from ExAC at a frequency of 0.0000494, which does not exceed the estimated maximal expected allele frequency of a pathogenic GBA variant (0.005). This variant is reported as one of the common pathogenic variants in literature found especially in Ashkenazi Jews population (Beutler_1991, Koprivica_2000, Brautbar_2003, Giraldo_2011). Functional data are consistent with predicted outcome of this variant because no translation product could be detected in an in vitro translation system and little or no enzyme antigen attributed to this allele could be found in cell lines from patients (Beutler_1991). Three clinical labs (via ClinVar) and a reputable database have classified this variant as pathogenic. Taken together, this variant has been classified as a pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
            <CitationText>LabCorp Variant Classification Summary - May 2015.docx</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <XRefList>
            <XRef DB="dbSNP" ID="387906315" Type="rsNumber" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001005741.2:c.84dupG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0017205" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2016-2017-variants</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="417238" SubmissionDate="2016-11-03" DateLastUpdated="2019-07-30" DateCreated="2015-06-28">
        <ClinVarSubmissionID localKey="16039_000000" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000228920" DateUpdated="2019-07-30" DateCreated="2015-06-28" Type="SCV" Version="4" SubmitterName="Eurofins Ntd Llc (ga)" OrgID="500060" OrganizationCategory="laboratory" OrgAbbreviation="EGL" />
        <RecordStatus>current</RecordStatus>
        <ReplacedList>
          <Replaced Accession="SCV000700345" DateChanged="2019-08-06" Version="1">
            <Comment Type="MergeComment">SCV000700345 was merged into SCV000228920 to remove duplication.</Comment>
          </Replaced>
          <Replaced Accession="SCV000111226" DateChanged="2018-02-14" Version="3" />
        </ReplacedList>
        <Classification DateLastEvaluated="2014-10-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">EGL Classification Definitions</Attribute>
          <Citation Type="general">
            <URL>http://www.egl-eurofins.com/emvclass/EGLClassificationDefinitions.php</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <Gender>mixed</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA" />
          </GeneList>
          <VariantType>Duplication</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="1" alternateAllele="C" referenceAllele="-" start="155210451" stop="155210452" variantLength="2" />
            <GeneLocation>NM_001005741.2:Ex3</GeneLocation>
          </Location>
          <XRefList>
            <XRef DB="HGMD" ID="CI910569" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">23757202</ID>
        </Citation>
        <Citation>
          <URL>http://geneticslab.emory.edu/emvclass/emvclass.php?approved_symbol=GBA</URL>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>EGL001</SubmissionName>
          <SubmissionName>EGL002</SubmissionName>
          <SubmissionName>EGL003</SubmissionName>
          <SubmissionName>EGL004</SubmissionName>
          <SubmissionName>EGL005</SubmissionName>
          <SubmissionName>PILOT_TEST_03</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2805093" SubmissionDate="2020-03-09" DateLastUpdated="2022-02-02" DateCreated="2020-07-19">
        <ClinVarSubmissionID localKey="63c92f1a-076d-4067-bf85-f7278faa8820|Orphanet:ORPHA355" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001422682" DateUpdated="2022-02-02" DateCreated="2020-07-19" Type="SCV" Version="2" SubmitterName="Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard" OrgID="506627" OrganizationCategory="laboratory" OrgAbbreviation="Broad RDG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-01-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10777718</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19513999</ID>
          </Citation>
          <Citation>
            <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/63c92f1a-076d-4067-bf85-f7278faa8820</URL>
          </Citation>
          <Comment>The p.Leu29AlafsTer18 variant in GBA has been reported in at least 70 individuals with Gaucher disease (PMID: 10777718, 19513999) and has been identified in 0.077% (8/10370) of Ashkenazi Jewish chromosomes, 0.006% (2/35440) of Latino chromosomes, and 0.002% (2/128886) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs387906315). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (VariationID: 4302) as pathogenic by EGL Genetic Diagnostics, Counsyl, Integrated Genetics, and OMIM. This variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at position 29 and leads to a premature termination codon 18 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the GBA gene is an established disease mechanism in autosomal recessive Gaucher disease. The presence of this variant in combination with a reported pathogenic variant and in 70 individuals with Gaucher disease increases the likelihood that the p.Leu29AlafsTer18 variant is pathogenic (VariationID: 4290; PMID: 10777718, 19513999). In summary, this variant meets criteria to be classified as pathogenic for Gaucher disease in an autosomal recessive manner based on the prediction that it causes loss of function and the presence of the variant in combination with a known pathogenic variant. ACMG/AMP Criteria applied: PVS1, PM3_very-strong, PM2_supporting (Richards 2015).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation Abbrev="ACMG, 2015" Type="practice guideline">
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_001005741.2(GBA):c.84dupG</Name>
            <Name>p.Leu29Alafs*18</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000001.11:g.155240661dupC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA355" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6906750</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4081648" SubmissionDate="2022-02-09" DateLastUpdated="2022-04-23" DateCreated="2022-04-23">
        <ClinVarSubmissionID localKey="NM_000157.4:c.84dup|Gaucher disease" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002086489" DateUpdated="2022-04-23" DateCreated="2022-04-23" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-03-17">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000157.4:c.84dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Gaucher disease</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10993736</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3483223" SubmissionDate="2022-02-16" DateLastUpdated="2023-03-04" DateCreated="2021-08-07">
        <ClinVarSubmissionID localKey="GDXSV:221254" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV001773668" DateUpdated="2023-03-04" DateCreated="2021-08-07" Type="SCV" Version="3" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-02-08">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Identified in the heterozygous state in patients with Parkinson disease, but also in control individuals (Ruskey et al., 2019; Gan-Or et al., 2015; Choi et al., 2011); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 10796875, 21228398, 25653295, 26096741, 22975760, 27717005, 25946768, 21700325, 29842932, 8889578, 7789963, 8516282, 34017912, 29471591, 17875915, 21742527, 1961718)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GBA" />
          </GeneList>
          <VariantType>Duplication</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:2714940</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001005741.2:c.84dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_20_20210805063641</SubmissionName>
          <SubmissionName>GeneDX_Clinvar_Submission_88_20220216054204</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3963891" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2291925" TraitType="Disease" MappingType="XRef" MappingValue="230800" MappingRef="OMIM">
        <MedGen CUI="C1961835" Name="Gaucher disease type I" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3255206" TraitType="Disease" MappingType="XRef" MappingValue="231000" MappingRef="OMIM">
        <MedGen CUI="C0268251" Name="Gaucher disease type III" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2805093" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA355" MappingRef="Orphanet">
        <MedGen CUI="C0017205" Name="Gaucher disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2291925" TraitType="Disease" MappingType="XRef" MappingValue="231005" MappingRef="OMIM">
        <MedGen CUI="C1856476" Name="Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="24717" TraitType="Disease" MappingType="Name" MappingValue="GAUCHER DISEASE, TYPE I" MappingRef="Preferred">
        <MedGen CUI="C1961835" Name="Gaucher disease type I" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5054060" TraitType="Disease" MappingType="XRef" MappingValue="C0017205" MappingRef="MedGen">
        <MedGen CUI="C0017205" Name="Gaucher disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="417238" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3255206" TraitType="Disease" MappingType="XRef" MappingValue="230900" MappingRef="OMIM">
        <MedGen CUI="C0268250" Name="Gaucher disease type II" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4892518" TraitType="Disease" MappingType="Name" MappingValue="Not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1363948" TraitType="Disease" MappingType="XRef" MappingValue="C0017205" MappingRef="MedGen">
        <MedGen CUI="C0017205" Name="Gaucher disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3255206" TraitType="Disease" MappingType="XRef" MappingValue="230800" MappingRef="OMIM">
        <MedGen CUI="C1961835" Name="Gaucher disease type I" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3483223" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3255206" TraitType="Disease" MappingType="XRef" MappingValue="168600" MappingRef="OMIM">
        <MedGen CUI="C3160718" Name="Parkinson disease, late-onset" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2354649" TraitType="Disease" MappingType="XRef" MappingValue="230800" MappingRef="OMIM">
        <MedGen CUI="C1961835" Name="Gaucher disease type I" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3255206" TraitType="Disease" MappingType="XRef" MappingValue="608013" MappingRef="OMIM">
        <MedGen CUI="C1842704" Name="Gaucher disease perinatal lethal" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2291925" TraitType="Disease" MappingType="XRef" MappingValue="231000" MappingRef="OMIM">
        <MedGen CUI="C0268251" Name="Gaucher disease type III" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2291925" TraitType="Disease" MappingType="XRef" MappingValue="230900" MappingRef="OMIM">
        <MedGen CUI="C0268250" Name="Gaucher disease type II" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1830772" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3255206" TraitType="Disease" MappingType="XRef" MappingValue="231005" MappingRef="OMIM">
        <MedGen CUI="C1856476" Name="Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4081648" TraitType="Disease" MappingType="Name" MappingValue="Gaucher disease" MappingRef="Preferred">
        <MedGen CUI="C0017205" Name="Gaucher disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3255206" TraitType="Disease" MappingType="XRef" MappingValue="127750" MappingRef="OMIM">
        <MedGen CUI="C0752347" Name="Lewy body dementia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

